Drilldown: Medicines

None (3) · Desvenlafaxine (succinate) (1) · Paroxetine (HCl; mesylate as Pexeva) (1)

Ajovy (1) · Emgality (1) · Paxil (IR), Paxil CR (controlled-release), Brisdelle (low-dose for menopausal vasomotor symptoms), Pexeva (paroxetine mesylate) (1) · Pristiq (1) · Sunosi (1)

Anti-CGRP ligand monoclonal antibody (2) · Norepinephrine-dopamine reuptake inhibitor (NDRI) (1) · wake-promoting agent (1) · [[:Category:Antidepressants|Antidepressant]] (2) · [[:Category:Anxiolytics|Anxiolytic]] (1) · [[:Category:SNRIs|Serotonin-norepinephrine reuptake inhibitor (SNRI)]] (1) · [[:Category:SSRIs|Selective serotonin reuptake inhibitor (SSRI)]] (1)

None (2) · Humanized IgG2 monoclonal antibody binding both isoforms of CGRP peptide (1) · Humanized IgG4 monoclonal antibody binding CGRP peptide; prevents CGRP from activating its receptor (1) · Selective dopamine and norepinephrine reuptake inhibitor (DAT and NET inhibition). Unlike amphetamine, does not significantly release monoamines, pure reuptake inhibition. (1)

Excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea (OSA) (1) · Preventive treatment of migraine in adults (episodic and chronic) (1) · Preventive treatment of migraine in adults; episodic cluster headache (1) · '"`UNIQ--vote-00000017-QINU`"', '"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"' (1) · '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"', '"`UNIQ--vote-00000026-QINU`"', '"`UNIQ--vote-00000027-QINU`"', '"`UNIQ--vote-00000028-QINU`"', '"`UNIQ--vote-00000029-QINU`"', '"`UNIQ--vote-0000002A-QINU`"' (1)

225 mg SC monthly, or 675 mg SC every 3 months (quarterly) (1) · 50 mg PO once daily ('''no titration required''', distinguishing it favorably from venlafaxine) (1) · MDD/GAD: 20 mg PO once daily. Panic disorder: 10 mg titrating to 40 mg. OCD: 20 mg titrating to 40-60 mg. CR: 25 mg/day. Brisdelle: 7.5 mg at bedtime for hot flashes (1) · Migraine: 240 mg SC loading dose, then 120 mg SC monthly. Cluster: 300 mg SC at onset of cluster period, then monthly during cluster. (1) · Narcolepsy: 75 mg PO once daily upon awakening, titrate every 3 days. OSA: 37.5 mg PO once daily, titrate. (1)

120 mg/mL prefilled syringe or autoinjector (1) · 225 mg/1.5 mL prefilled syringe or autoinjector (1) · 75 mg, 150 mg tablets (1) · ER tablets 25, 50, 100 mg (1) · IR tablets 10, 20, 30, 40 mg; CR tablets 12.5, 25, 37.5 mg; oral suspension 10 mg/5 mL; Brisdelle capsules 7.5 mg (1)

150 mg/d (1) · 240 mg loading + 120 mg/month for migraine; 300 mg/month for cluster (1) · 50 mg/day (IR); 62.5 mg/day (CR); 60 mg/day (OCD) (1) · 50 mg/day (no efficacy benefit shown for higher doses despite the 100 mg strength being available) (1) · 675 mg/quarter (1)

Oral (3) · Subcutaneous (2)

None · Hours · 30-60 minutes · 1-2 hours · ~30 min · LDL lowering at 2 weeks, max by 4 weeks · ~1 hour · 15-30 minutes · 15–30 min · 1–2 h · 30–60 min · Antidepressant effect emerges over 1-2 weeks · BP and symptomatic LUTS improvement within 1-2 weeks · BP effect within 1-2 weeks · Clinical improvement within 24-72 hours · Days · Motor improvement over days at therapeutic dose · Over weeks · Postprandial glucose effect within days; HbA1c by 12 weeks · Sleep effect from first dose; antidepressant effect over 1-4 weeks

Other values:

Search

24 hours (1) · 24 hours (once-daily dosing) (1) · Monthly dosing (1) · Monthly or quarterly dosing (1) · ~9 hours (1)

~11 hours'"`UNIQ--ref-0000001A-QINU`"' (1) · ~21 hours (with nonlinear pharmacokinetics from CYP2D6 autoinhibition)'"`UNIQ--ref-0000002B-QINU`"' (1) · ~27 days (1) · ~31 days (1) · ~7.1 hours (1)

Highly variable due to saturable first-pass metabolism'"`UNIQ--ref-0000002C-QINU`"' (1) · Not formally established (1) · Not formally established (high SC) (1) · ~80% (oral)'"`UNIQ--ref-0000001B-QINU`"' (1) · ~95% (1)

'''Among the least preferred SSRIs in pregnancy.''' Observational signal for cardiac malformations (atrial and ventricular septal defects) with first-trimester exposure, and the most severe neonatal adaptation syndrome of any SSRI with third-trimester exposure'"`UNIQ--ref-0000002D-QINU`"' (1) · Limited data; avoid (2) · Limited data; pregnancy exposure registry available (1) · Observational signal for neonatal adaptation syndrome with late-pregnancy exposure (SNRI class effect).<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

Rx (2) · Rx, Schedule IV (US) (1) · [[USLegal:Prescription only|Rx-only]] in US. Carries the antidepressant '''Boxed Warning''' for suicidality in children, adolescents, and young adults'"`UNIQ--ref-0000001C-QINU`"' (1) · [[USLegal:Prescription only|Rx-only]] in US. Carries the antidepressant '''Boxed Warning''' for suicidality in children, adolescents, and young adults'"`UNIQ--ref-0000002E-QINU`"' (1)